Clinical trials: Cancer, Gastrointestinal
Hepatocellular Carcinoma
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
This study will look at whether adding daily oral zinc supplements to targeted therapy plus immunotherapy may help people with unresectable or advanced hepatocellular carcinoma, a common type of liver cancer.
- Trial name
- ZINC-1LT/IOHCC (NCT07793695)
- Testing
- Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8
- Trial name
- NCT05296681
- Testing
- NBT-NM108
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Howard S. Hochster, MD
Head and Neck Neoplasm, Gastrostomy
Endoscopic Direct-PEG Placement in Patients Unable to Undergo Pull-PEG Procedure
Placement of a feeding tube through a gastrostomy can be performed endoscopically or radiologically. While percutaneous endoscopic gastrostomy (PEG) tube placement is most frequently performed using a "pull" technique, this…
- Conditions
- Head and Neck Neoplasm, Gastrostomy, Esophageal Stenosis and Obstruction
- Trial name
- PEG (NCT04151030)
- Testing
- PEG placement
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Kansas City Veteran Affairs Medical Center
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Esophageal Cancer, Esophageal Neoplasms
Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer
This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related…
- Conditions
- Esophageal Cancer, Esophageal Neoplasms, Gastric Cancer, Stomach Neoplasm
- Trial name
- NCT05698992
- Testing
- evidence-based individualized rehabilitation
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane
Primary Visceral Tumors of Any Histotype, Visceral Lesions
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy.
- Conditions
- Primary Visceral Tumors of Any Histotype, Visceral Lesions, Liver Cancer, Liver Metastasis Colon Cancer
- Trial name
- NCT06753136
- Testing
- percutaneous, laparoscopic or laparotomy lesion electrochemotherapy
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (Disorder)
Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy
People with inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease affecting the colon, have a higher risk of developing colon cancer over time.
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (Disorder), Crohns Disease, Colorectal Neoplasms
- Trial name
- NCT07089771
- Testing
- Virtual Chromoendoscopy, Dye-Based Chromoendoscopy
- Where
- Sweden
- Volunteers
- 480 people
- Sponsor
- Region Stockholm
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Gastric Cancer
Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer
This is a prospective, single-center, open, historically controlled real-world study. The aims of this study is to evaluate the safety and effectiveness of Nab-paclitaxel combined with oxaliplatin and S-1 in the treatment of…
- Trial name
- NCT05052931
- Testing
- Nab-paclitaxel combined with oxaliplatin and S-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jianjun Yang
Esophageal Cancer, Gastric (Stomach) Cancer
Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Purpose of the Study: This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or…
- Conditions
- Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Trial name
- OMEC-5 (NCT07000253)
- Testing
- Chemotherapy, Targeted Systemic Therapy, Immunotherapy
- Where
- 5 sites in Netherlands, Norway and 1 more
- Volunteers
- 290 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Gastric Neoplasm, Artificial Intelligence
Miss Rate of Gastric Neoplasms Under Computer-aided Endoscopy
This prospective randomized trial compares AI-assisted upper gastrointestinal endoscopy with high definition upper gastrointestinal endoscopy in term of missed rate of gastric neoplasm.
- Trial name
- NCT06495645
- Testing
- AI-assisted upper gastrointestinal endoscopy
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- The University of Hong Kong
Gastrointestinal Stromal Tumors
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting.
- Trial name
- NCT00877045
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- SCRI Development Innovations, LLC
Barrett Esophagus, Barretts Esophagus With Dysplasia
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy.
- Conditions
- Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Esophageal Adenocarcinoma
- Trial name
- SOS4C (NCT06071845)
- Testing
- Cytosponge Procedure, Endoscopic Assessment
- Where
- 5 sites in United States
- Volunteers
- 450 people
- Sponsor
- Mayo Clinic
Colorectal Neoplasms
Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance
From observational studies, it is know that the risk of developing colorectal cancer after polyp removal is lower if the patients adheres to surveillance recommendations.
- Trial name
- NCT06983639
- Testing
- Fecal occult blood testing, Colonoscopy
- Where
- Norway
- Volunteers
- 4,000 people
- Sponsor
- Sorlandet Hospital HF
Bladder Cancer, Breast Cancer
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors.
- Conditions
- Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer
- Trial name
- TTBF (NCT05056077)
- Testing
- Counseling, Educational Intervention, Health Education
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- University of California, San Francisco
Colonic Neoplasms, Colorectal Neoplasms
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054912
- Testing
- EP2101
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
Hepatocellular Carcinoma, Liver Cancer
Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC
BACKGROUND: Hepatocellular carcinoma is the fifth most frequent cancer in the world, with a diagnosis of more than 500,000 new cases per year.
- Trial name
- NCT04653701
- Testing
- Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juan José Ciampi Dopazo
Pancreatic Cancer
Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer
The aim of this study was to compare the therapeutic efficacy between simultaneous gemcitabine administration and IRE and IRE alone for locally advanced pancreatic cancer (LAPC)
- Trial name
- NCT02981719
- Testing
- simultaneous gemcitabine and irreversible electroporation, irreversible electroporation
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Colorectal Neoplasms
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
Limited agents are optional after standard first and second line treatment for mCRC. Only Regorafenib and Fruquintinib are approved in China. PFS of these targeted drugs are not very long.
- Trial name
- NCT04683965
- Testing
- Pemetrexed, TAS-102, Bevacizumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
- Trial name
- NCT06657144
- Testing
- CHS-114, Toripalimab, 5 Fluorouracil
- Where
- 30 sites in United States, Taiwan
- Volunteers
- 154 people
- Sponsor
- Coherus Oncology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.